ClinicalTrials.gg
CompletedNCT02224560GWPCARE3Updated Sep 28, 2022Results posted

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

A Phase 3 interventional study of GWP42003-P and Placebo control in Epilepsy and Lennox Gastaut Syndrome, sponsored by Jazz Pharmaceuticals. Completed at 29 sites in 4 countries. Open to participants aged 2 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Primary conditionLennox Gastaut SyndromeRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lennox Gastaut Syndrome
Why
  1. The study's listed conditions name Lennox Gastaut Syndrome, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
2 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing cannabidiol in Lennox Gastaut Syndrome — 2 open to participants now, 3 under way, none of them phase 3. Cannabidiol · Lennox Gastaut Syndrome.

Enrollment
2nd of 13
225 · median 40
Started
2015
with 2 others
Phase 3
7 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
6 of 13
Jazz Pharmaceuticals

Among the 13 studies testing cannabidiol in Lennox Gastaut Syndrome, this one is the 2nd largest by enrollment, is one of 3 that started in 2015, is one of 7 in phase 3, and was the 1st registered.

Lennox Gastaut Syndrome

68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.

Browse Lennox Gastaut Syndrome studies →

Open to participants now

2 of the 13 studies testing cannabidiol in Lennox Gastaut Syndrome are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 4 Lennox Gastaut Syndrome studies recruiting now, none set no upper age limit and 4 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 2 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing cannabidiol in Lennox Gastaut Syndrome, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).

Read the detailed description

This study was a 1:1:1 randomized, double-blind, 14-week comparison of 2 dose levels (10 milligram [mg] per kilogram [kg] per day [mg/kg/day] and 20 mg/kg/day) of GWP42003-P versus placebo. Participants who satisfied all inclusion and none of the exclusion criteria began a 28-day baseline observation period. The treatment period consisted of a 2-week titration period followed by a 12-week maintenance period. The 20 mg/kg/day dose was recommended by the Data Safety Monitoring Committee (DSMC) after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose. The first participant was not enrolled into this study until the DSMC had reviewed the safety data from Part A of study GWEP1332.

Participants who satisfied all eligibility criteria were randomized at Day 1 to receive 10 mg/kg/day GWP42003-P, 20 mg/kg/day GWP42003-P, or placebo at a 1:1:1 ratio. Participants in the placebo group were split into 2 equivalent cohorts; one half received 10 mg/kg/day dosing volumes and one half received 20 mg/kg/day dosing volumes. The 2 placebo cohorts were pooled for the analyses of efficacy. Participants titrated GWP42003-P to the 10 mg/kg/day or 20 mg/kg/day (or equivalent volume of placebo) dose over 7 and 11 days, respectively, and remained at this dose for the 12-week maintenance period. Following the end of treatment (Day 99), participants were invited to continue to receive GWP42003-P in an open-label extension (OLE) study under a separate protocol (GWEP1415; NCT02224573). All participants who did not immediately enter the OLE study tapered investigational medicinal product (IMP) (10% per day over 10 days). However, the taper period could be interrupted if the participant wished to enter the OLE study within a 7-day timeframe. Participants who down-titrated IMP returned for an end of taper period visit (Day 109). Participants who did not enter the OLE study or who withdrew prematurely had a safety follow-up visit 28 days later (Day 137).

03

Conditions studied

  • Epilepsy
  • Lennox Gastaut Syndrome

Browse trials for

Keywords

  • Cannabidiol
  • CBD
  • Epidiolex
  • GWP42003-P
04

In context

Lennox Gastaut Syndrome Reclassified

68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.

This study's enrollment of 225 is above the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.

Browse Lennox Gastaut Syndrome studies →

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Compared within Lennox Gastaut Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant and/or parent(s)/legal representatives were willing and able to give informed assent/consent for participation in the study.
  • Participant and his or her caregivers were willing and able (in the investigator's opinion) to comply with all study requirements.
  • Participant was male or female aged between 2 and 55 years (inclusive).
  • Participant had a documented history of LGS. This included written documentation of having met electroencephalogram (EEG) diagnostic criteria during the participant's history and evidence of at least 1 type of generalized seizure, including drop seizures (atonic, tonic, tonic-clonic or myoclonic) for at least 6 months.
  • Participant had a history of slow (\<3.0 hertz [Hz]) spike-and-wave pattern in an EEG prior to the enrollment into the baseline period.
  • Participant had at least 2 drop seizures each week during the first 28 days of the baseline period.
  • Participant was ; that is having documented failures on more than 1 antiepileptic drug (AED).
  • Participant was taking 1 or more AEDs at a dose which had been stable for at least 4 weeks prior to screening.
  • All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation [VNS]) were stable for 4 weeks prior to screening and the participant was willing to maintain a stable regimen throughout the study. The ketogenic diet and VNS treatments were not counted as an AED.
  • Participant and/or parent(s)/legal representatives were willing to allow his or her primary care practitioner and consultant to be notified of participation in the study.
  • Participant completed his or her interactive voice response (IVRS) telephone diary on at least 25 days of the baseline period.

Key Exclusion Criteria:

  • Etiology of participant's seizures was a progressive neurologic disease. Participants with tuberous sclerosis were not excluded from study participation, unless there was a progressive tumor.
  • Participant had an anoxic episode requiring resuscitation within 6 months of screening.
  • Participant had unstable medical conditions other than epilepsy.
  • Participant had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to screening or randomization, other than epilepsy.
  • Participant had a history or presence of alcohol or substance abuse within the last 2 years prior to the study or daily consumption of 5 or more alcohol-containing beverages.
  • Participant was currently using or had in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to study entry and was unwilling to abstain for the duration of the study.
  • Participant had a history of symptoms (for example, dizziness, light-headedness, blurred vision, palpitations, weakness, syncope) related to a drop in blood pressure due to postural changes.
  • Participant had any known or suspected to cannabinoids or any of the of the IMP, such as sesame oil.
  • Female participant was of child bearing potential or male participant's partner was of child bearing potential; unless willing to ensure that they or their partner used a highly effective method of for the duration of the study and for 3 months thereafter.
  • Female participant was pregnant (positive pregnancy test), lactating or planning pregnancy during the course of the study and for 3 months thereafter.
  • Participant had been part of a clinical study involving another IMP in the previous 6 months.
  • Patient had significantly impaired hepatic function at screening (Day -28) or randomization (Day 1), defined as any of the following: (ALT) or aspartate aminotransferase (AST) > 5 × (ULN); ALT or AST > 3 × ULN and total > 2 × ULN or (INR) > 1.5; ALT or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%). This criterion could only be confirmed once the laboratory results were available; participants randomized into the study who were later found not to meet this criterion were withdrawn from the study.
  • Any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale in the last month or at screening.
  • Participant was unwilling to abstain from donation of blood during the study.
  • Participant planned to travel outside his or her country of residence during the study.
  • Participant had previously randomized into the study.
  • Participant was taking more than 4 concurrent AEDs.
  • Participant had taken corticotropins in the 6 months prior to screening.
  • Participant was currently taking long-term systemic (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception was made of prophylactic medication, for example, idiopathic nephrotic syndrome or asthma.
  • Participant was taking felbamate, and he or she had been taking it for less than 1 year prior to screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    GWP42003-P 20 mg/kg/day Dose

    Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.

    Drug: GWP42003-P

  • Experimental
    GWP42003-P 10 mg/kg/day Dose

    Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.

    Drug: GWP42003-P

  • Placebo comparator
    Placebo

    Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.

    Drug: Placebo control

Interventions

  • GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.

    Also known as: Cannabidiol, Epidiolex

  • DrugPlacebo control

    Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).

    Also known as: Placebo

07

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period

    Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (\[frequency during the treatment period - frequency during baseline\]/frequency during baseline) x 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) x 28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.

    Time frame: Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)

Secondary outcomes

  1. Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period

    Drop seizures were recorded by the participant or caregiver using an IVRS diary. Drop seizures included the subset of tonic-clonic, tonic, or atonic seizures that were reported as drop seizures in IVRS. Percentage change from baseline was calculated as per the primary outcome measure.

    Time frame: Baseline to EOT (Day 99) or ET

  2. Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period

    Total seizures included the sum of all seizures (tonic-clonic, tonic, atonic, clonic, myoclonic, countable partial, other partial, and absence seizures) recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Negative percentages show an improvement from baseline.

    Time frame: Baseline to EOT (Day 99) or ET

  3. Subject/Caregiver Global Impression Of Change (S/CGIC) Assessment

    The S/CGIC was used to assess the participant's overall condition on a 7-point scale, using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the S/CGIC questionnaire at subsequent visits. If both a CGIC and SGIC were completed then the CGIC was used; if only a CGIC was completed then the CGIC was used; if only a SGIC was completed then the SGIC was used. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.

    Time frame: Baseline to Last Visit (Day 99) or ET

08

Results

Posted Jul 27, 2018

Participant flow

Participant flow — Overall Study
MilestoneGWP42003-P 20 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DosePlacebo
Started767376
Safety analysis set826776
Intent to treat (itt) analysis set767376
Completed677174
Not completed922
Withdrew: Protocol deviation100
Withdrew: Withdrawal by subject201
Withdrew: Met withdrawal criteria100
Withdrew: Adverse event411
Withdrew: Withdrawn by investigator110

Outcome measures

PrimaryPercentage Change From Baseline In Drop Seizure Frequency During The Treatment Period

Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (\[frequency during the treatment period - frequency during baseline\]/frequency during baseline) x 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) x 28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.

Time frame:
Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)
Reported as:
Median · percentage change
Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
percentage changeGWP42003-P 20 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DosePlacebo
Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period-41.86 (-72.4 to -1.3)-37.16 (-63.8 to -5.6)-17.17 (-37.1 to 0.9)
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Wilcoxon rank-sum test · p = 0.0047 · Median difference (final values): -21.57 · 95% CI -34.79 to -6.67Calculated using the Hodges-Lehmann approach
  • GWP42003-P 10 mg/kg/Day Dose vs Placebo · Wilcoxon rank-sum test · p = 0.0016 · Median difference (final values): -19.19 · 95% CI -31.24 to -7.69Calculated using the Hodges-Lehmann approach
SecondaryNumber Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period

Drop seizures were recorded by the participant or caregiver using an IVRS diary. Drop seizures included the subset of tonic-clonic, tonic, or atonic seizures that were reported as drop seizures in IVRS. Percentage change from baseline was calculated as per the primary outcome measure.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Count of participants · Participants
Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period
ParticipantsGWP42003-P 20 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DosePlacebo
Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period302611
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0006 (Calculated using a Cochran-Mantel-Haenszel (CMH) test stratified by age group (2-5, 6-11, 12-17 and 18-55 years)) · Odds ratio (or): 3.85 · 95% CI 1.75 to 8.47
  • GWP42003-P 10 mg/kg/Day Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0030 (Calculated using a CMH test stratified by age group (2-5, 6-11, 12-17 and 18-55 years)) · Odds ratio (or): 3.27 · 95% CI 1.47 to 7.26
SecondaryPercentage Change From Baseline In Total Seizure Frequency During The Treatment Period

Total seizures included the sum of all seizures (tonic-clonic, tonic, atonic, clonic, myoclonic, countable partial, other partial, and absence seizures) recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Negative percentages show an improvement from baseline.

Time frame:
Baseline to EOT (Day 99) or ET
Reported as:
Median · percentage change
Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
percentage changeGWP42003-P 20 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DosePlacebo
Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period-38.40 (-64.6 to -0.7)-36.44 (-64.5 to -10.8)-18.47 (-39.0 to 0.5)
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Wilcoxon rank-sum test · p = 0.0091 · Median difference (final values): -18.76 · 95% CI -31.80 to -4.43Calculated using the Hodges-Lehmann approach
  • GWP42003-P 10 mg/kg/Day Dose vs Placebo · Wilcoxon rank-sum test · p = 0.0015 · Median difference (final values): -19.47 · 95% CI -30.37 to -7.47Calculated using the Hodges-Lehmann approach
SecondarySubject/Caregiver Global Impression Of Change (S/CGIC) Assessment

The S/CGIC was used to assess the participant's overall condition on a 7-point scale, using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the S/CGIC questionnaire at subsequent visits. If both a CGIC and SGIC were completed then the CGIC was used; if only a CGIC was completed then the CGIC was used; if only a SGIC was completed then the SGIC was used. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.

Time frame:
Baseline to Last Visit (Day 99) or ET
Reported as:
Count of participants · Participants
Subject/Caregiver Global Impression Of Change (S/CGIC) Assessment
ParticipantsGWP42003-P 20 mg/kg/Day DoseGWP42003-P 10 mg/kg/Day DosePlacebo
Very Much Improved691
Much Improved15148
Slightly Improved222524
No Change252135
Slightly Worse634
Much Worse113
Very Much Worse000
Statistical analysis
  • GWP42003-P 20 mg/kg/Day Dose vs Placebo · Regression, Logistic · p = 0.0439 · Odds ratio (or): 1.83 · 95% CI 1.02 to 3.30Odds of participant recording a lower score (improvement) on a continuous scale
  • GWP42003-P 10 mg/kg/Day Dose vs Placebo · Regression, Logistic · p = 0.0020 · Odds ratio (or): 2.57 · 95% CI 1.41 to 4.66Odds of participant recording a lower score (improvement) on a continuous scale

Adverse events

Collected over Day 1 through Day 137 (Safety Follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GWP42003-P 20 mg/kg/Day Dose-Safety Analysis Set—13/82 (15.9%)63/82 (76.8%)
GWP42003-P 10 mg/kg/Day Dose-Safety Analysis Set—13/67 (19.4%)36/67 (53.7%)
Placebo-Safety Analysis Set—8/76 (10.5%)40/76 (52.6%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventGWP42003-P 20 mg/kg/Day Dose-Safety Analysis SetGWP42003-P 10 mg/kg/Day Dose-Safety Analysis SetPlacebo-Safety Analysis Set
Status epilepticusNervous system disorders4/827/673/76
PneumoniaInfections and infestations2/823/670/76
ConvulsionNervous system disorders2/820/670/76
PancreatitisGastrointestinal disorders0/821/670/76
Cholecystitis chronicHepatobiliary disorders0/821/670/76
Pneumonia bacterialInfections and infestations0/821/670/76
Pneumonia respiratory syncytial viralInfections and infestations0/821/670/76
Aspartate aminotransferase increasedInvestigations1/821/670/76
Transaminases increasedInvestigations0/821/670/76
DehydrationMetabolism and nutrition disorders0/821/670/76
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGWP42003-P 20 mg/kg/Day Dose-Safety Analysis SetGWP42003-P 10 mg/kg/Day Dose-Safety Analysis SetPlacebo-Safety Analysis Set
SomnolenceNervous system disorders25/8214/674/76
Decreased appetiteMetabolism and nutrition disorders21/8211/676/76
Upper respiratory tract infectionInfections and infestations10/8211/6711/76
PyrexiaGeneral disorders9/826/6712/76
DiarrhoeaGastrointestinal disorders12/827/676/76
VomitingGastrointestinal disorders10/824/679/76
NasopharyngitisInfections and infestations9/823/675/76
FatigueGeneral disorders8/825/672/76
ConvulsionNervous system disorders5/822/677/76
IrritabilityPsychiatric disorders4/826/672/76

Baseline characteristics

ITT Analysis Set: Received at least 1 dose of IMP with at least 1 post-baseline efficacy endpoint measurement. Participants were analyzed according to the treatment group to which they were randomized.

Age, Continuous
Age, Continuous(years)GWP42003-P 20 mg/kg/Day Dose-ITT Analysis SetGWP42003-P 10 mg/kg/Day Dose-ITT Analysis SetPlacebo-ITT Analysis SetTotal
Mean16.0 ± 10.815.4 ± 9.515.3 ± 9.315.6 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P 20 mg/kg/Day Dose-ITT Analysis SetGWP42003-P 10 mg/kg/Day Dose-ITT Analysis SetPlacebo-ITT Analysis SetTotal
Female31333296
Male454044129
09

Study locations

29 sites
  • Birmingham, Alabama 35294, United States
  • Phoenix, Arizona 85054, United States
  • Los Angeles, California 90027, United States
  • Hartford, Connecticut 06106, United States
  • Orlando, Florida 32819, United States
  • Augusta, Georgia 30912, United States
  • Boise, Idaho 83702, United States
  • Rochester, Minnesota 55905, United States
  • Buffalo, New York 14222, United States
  • New York, New York 10003, United States
  • New York, New York 10016, United States
  • Clemmons, North Carolina 27012, United States
  • Winston-Salem, North Carolina 27157, United States
  • Cincinnati, Ohio 45267, United States
  • Columbus, Ohio 43205, United States
  • York, Pennsylvania 17403, United States
  • Charleston, South Carolina 29425, United States
  • Austin, Texas 78723, United States
  • Fort Worth, Texas 76104, United States
  • Charlottesville, Virginia 22903, United States
  • Paris, 75015, France
  • Barcelona, 08022, Spain
  • Madrid, 28034, Spain
  • Pamplona, 31080, Spain
  • Sevilla, 41013, Spain
  • Valencia, 46026, Spain
  • Edinburgh, EH9 1LF, United Kingdom
  • Glasgow, G51 4TF, United Kingdom
  • London, WC1N 3JH, United Kingdom
10

References and documents

Publications

  • Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. PubMed 29768152 ↗
  • Brigo F, Jones K, Eltze C, Matricardi S. Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021 Apr 7;4(4):CD003277. doi: 10.1002/14651858.CD003277.pub4. PubMed 33825230 ↗
  • Privitera M, Bhathal H, Wong M, Cross JH, Wirrell E, Marsh ED, Mazurkiewicz-Beldzinska M, Villanueva V, Checketts D, Knappertz V, VanLandingham K. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials. Epilepsia. 2021 May;62(5):1130-1140. doi: 10.1111/epi.16878. Epub 2021 Apr 2. PubMed 33797076 ↗
  • Perry MS. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy. Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671. PubMed 30955420 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in May 2016, 11 months.

Results were first posted in Jul 2018, 2 years 2 months after primary completion. A results delay was requested in Sep 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2014
First posted
Aug 25, 2014
StartActual
Jun 8, 2015
Primary completionActual
May 19, 2016
CompletionActual
May 19, 2016
Results delay requested
Sep 18, 2017
Results first posted
Jul 27, 2018
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02224560
Responsible party
Sponsor
First posted
Aug 25, 2014
Start date
Jun 8, 2015
Primary completion
May 19, 2016
Completion
May 19, 2016
Results posted
Jul 27, 2018
Last update
Sep 28, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion